Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05052801 |
|---|---|
| Brief Title: | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) |
| First Submitted : | September 13, 2021 |
| First Submitted that Met QC Criteria : | September 13, 2021 |
| First Posted : | September 22, 2021 |
| Last Update Submitted that Met QC Criteria : | May 15, 2024 |
| Last Update Posted : | May 16, 2024 |